On top of reducing hyperglycemia and improving insulin action, pioglitazone or rosiglitazone treatment of individuals with type 2 diabetes (T2DM) was associated with remarkable improvements in plasma triglyceride and HDL-C levels and in LDL particle concentration and size [112,113,114,115]. Here, INS is linked to type 2 diabetes mellitus.